| Each indication below has been associated with increased mortality, thus eligible for any types of HCT (with moderate to high risk of HCT related complications) |
Stroke or clinically significant neurologic event or deficit lasting >24 hr 2 or more episodes of ACS in the 2-year period preceding HCT, despite supportive care (ie. asthma therapy, HU, and/or regular transfusion program) 2 or more VOC per year in the 2-year period preceding HCT, despite supportive care (ie, HU, pain management plan, and/or regular transfusion program) tricuspid regurgitant jet velocity ≥2.7 m/s on echo regular RBC transfusion therapy (≥8 transfusions per year for ≥ 1 yr) to prevent vaso-occlusive complications (ie, VOC, stroke, abnormal TCD, or ACS)
|
| Each indication below has been associated with substantial morbidity, thus eligible for low risk HCT. If 2 or more indications, then eligible for moderate risk HCT in the context of clinical trials |
Impaired neuropsychological function with abnormal cerebral MRI and angiography, Walters et al (2016)[38] Sickle nephropathy (moderate or severe proteinuria, glomerular filtration rate 30 to 50% of the predicted normal value, or serum creatinine ≥1.5 times the upper limit of normal), Powars et al (1993)[45] Sickle liver disease (direct bilirubin >0.4 mg/dL or ferritin >1000 ng/L), Feld et al (2015)[46] Osteonecrosis of multiple joints Red-cell alloimmunization during long-term transfusion therapy
|
| Indications that have been largely replaced by the above criteria |
|
|
